These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 26517983)

  • 1. Are there any potentially dangerous pharmacological effects of combining ADHD medication with alcohol and drugs of abuse? A systematic review of the literature.
    Barkla XM; McArdle PA; Newbury-Birch D
    BMC Psychiatry; 2015 Oct; 15():270. PubMed ID: 26517983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse Drug Reactions Related to Mood and Emotion in Pediatric Patients Treated for Attention Deficit/Hyperactivity Disorder: A Comparative Analysis of the US Food and Drug Administration Adverse Event Reporting System Database.
    Pozzi M; Carnovale C; Mazhar F; Peeters GGAM; Gentili M; Nobile M; Radice S; Clementi E
    J Clin Psychopharmacol; 2019; 39(4):386-392. PubMed ID: 31205193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
    Roskell NS; Setyawan J; Zimovetz EA; Hodgkins P
    Curr Med Res Opin; 2014 Aug; 30(8):1673-85. PubMed ID: 24627974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Pharmacotherapy of Adults With Attention Deficit Hyperactivity Disorder: A Literature Review and Clinical Study.
    Fredriksen M; Peleikis DE
    Basic Clin Pharmacol Toxicol; 2016 Jan; 118(1):23-31. PubMed ID: 26404187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
    Stuhec M; Munda B; Svab V; Locatelli I
    J Affect Disord; 2015 Jun; 178():149-59. PubMed ID: 25813457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.
    Elliott J; Johnston A; Husereau D; Kelly SE; Eagles C; Charach A; Hsieh SC; Bai Z; Hossain A; Skidmore B; Tsakonas E; Chojecki D; Mamdani M; Wells GA
    PLoS One; 2020; 15(10):e0240584. PubMed ID: 33085721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry.
    Cortese S; Panei P; Arcieri R; Germinario EA; Capuano A; Margari L; Chiarotti F; Curatolo P
    CNS Drugs; 2015; 29(10):865-77. PubMed ID: 26293742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.
    Eiland LS; Bell EA; Erramouspe J
    Ann Pharmacother; 2014 Oct; 48(10):1350-5. PubMed ID: 24982313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database.
    McCarthy S; Cranswick N; Potts L; Taylor E; Wong IC
    Drug Saf; 2009; 32(11):1089-96. PubMed ID: 19810780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
    Su Y; Yang L; Stein MA; Cao Q; Wang Y
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders.
    Kollins SH
    Curr Med Res Opin; 2008 May; 24(5):1345-57. PubMed ID: 18384709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity disorder and addiction.
    Pérez de los Cobos J; Siñol N; Pérez V; Trujols J
    Br J Clin Pharmacol; 2014 Feb; 77(2):337-56. PubMed ID: 23216449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study.
    Wong IC; Asherson P; Bilbow A; Clifford S; Coghill D; DeSoysa R; Hollis C; McCarthy S; Murray M; Planner C; Potts L; Sayal K; Taylor E
    Health Technol Assess; 2009 Oct; 13(50):iii-iv, ix-xi, 1-120. PubMed ID: 19883527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents.
    Cortese S; Holtmann M; Banaschewski T; Buitelaar J; Coghill D; Danckaerts M; Dittmann RW; Graham J; Taylor E; Sergeant J;
    J Child Psychol Psychiatry; 2013 Mar; 54(3):227-46. PubMed ID: 23294014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
    Najib J
    Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ADHD Medication and Substance-Related Problems.
    Quinn PD; Chang Z; Hur K; Gibbons RD; Lahey BB; Rickert ME; Sjölander A; Lichtenstein P; Larsson H; D'Onofrio BM
    Am J Psychiatry; 2017 Sep; 174(9):877-885. PubMed ID: 28659039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ADHD update: new data on the risks of medication.
    Harv Ment Health Lett; 2006 Oct; 23(4):3-5. PubMed ID: 17183739
    [No Abstract]   [Full Text] [Related]  

  • 18. Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006.
    Harpin VA
    Arch Dis Child Educ Pract Ed; 2008 Apr; 93(2):58-65. PubMed ID: 18356307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of attention-deficit/hyperactivity disorder.
    Jadad AR; Boyle M; Cunningham C; Kim M; Schachar R
    Evid Rep Technol Assess (Summ); 1999 Nov; (11):i-viii, 1-341. PubMed ID: 10790990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): an open-label prospective study of time in treatment, dose, side-effects and comorbidity.
    Fredriksen M; Dahl AA; Martinsen EW; Klungsøyr O; Haavik J; Peleikis DE
    Eur Neuropsychopharmacol; 2014 Dec; 24(12):1873-84. PubMed ID: 25453480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.